Heidelberg Pharma AG (HPHA) AI Stock Analysis

• Market Cap: €215.30M
• Dividend Yield: N/A
• Average Volume (3M): 19.73K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: -24.29%
• EPS Growth: -13.92%
• Country: DE
• Employees: 105
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 46,601,097
• 10 Day Avg. Volume: 8,044
• 30 Day Avg. Volume: 19,729
• PEG Ratio: 0.31
• Price to Book (P/B): 3.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -22.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €4.00
• Price Target Upside: -13.42% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 56 Neutral
• Price Target: €5.00 ▲(8.23%Upside)

Heidelberg Pharma AG's overall score reflects a mix of financial challenges and technical strength. The primary risk comes from its weak financial performance, with significant operating losses and negative cash flows. However, its strong technical indicators suggest positive market sentiment and potential short-term price gains. The poor valuation due to a negative P/E ratio further highlights the need for caution.

Heidelberg Pharma AG Business Overview & Revenue Model

Company Description

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing HDP-102 for the treatment of non-Hodgkin lymphoma; HDP-103, an ATAC candidate to treat metastatic castration-resistant prostate cancer; HDP-104 for tumors; and HDP-XX for the treatment of solid/hematological tumors. The company is also developing MGTA-ATACs for HSCs, conditioning programs to treat blood cancers/genetic diseases; TAK-ATACs for oncology; and TLX250-CDx, a diagnostic antibody for imaging diagnostics of renal cancer in Phase III trials; urothelial carcinoma or bladder cancer in Phase I study; and triple-negative breast cancer in Phase II study. In addition, the company develops TLX250 (girentuximab), a therapeutic antibody, which is in Phase II study for patients with advanced clear cell renal cell carcinoma; RHB-107, an oral serine protease inhibitor that is in Phase II/III study to treat COVID-19, as well as for the treatment of advanced cholangiocarcinoma; and LH011 for pancreatic cancer. It has licensing agreement and strategic partnership with Huadong Medicine Co., Ltd. for the development and commercialization rights for HDP-101 and HDP-103 in Asia. The company was formerly known as Wilex AG and changed its name to Heidelberg Pharma AG in October 2017. Heidelberg Pharma AG was founded in 1997 and is based in Ladenburg, Germany.

How the Company Makes Money

Heidelberg Pharma AG generates revenue through a combination of licensing agreements, collaborations, and partnerships with other pharmaceutical and biotechnology companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and potential royalties on sales of successfully commercialized products. The company may also receive research funding from these collaborations to advance its ATAC technology and pipeline. Additionally, Heidelberg Pharma may engage in strategic partnerships to co-develop or out-license its proprietary technologies, thereby expanding its reach and financial potential in the oncology therapeutics market.

Heidelberg Pharma AG Financial Statement Overview

Summary

Heidelberg Pharma AG is facing financial challenges with declining revenues, significant operating losses, and negative cash flows. The balance sheet shows some stability, but high liabilities and declining equity pose risks. Improvement in operational efficiency and financial management is needed.

Income Statement

Heidelberg Pharma AG shows decreasing revenue and negative profit margins, with a declining revenue growth rate from recent years. The company struggles with high EBIT and EBITDA losses, indicating operational inefficiencies.

Balance Sheet

The balance sheet displays a moderate debt-to-equity ratio and a reasonable equity ratio. However, the declining stockholders' equity and high total liabilities indicate potential financial instability.

Cash Flow

The company exhibits negative operating and free cash flows, which could affect its liquidity. Free cash flow has been consistently negative, but financing activities provide some cash influx. The ratios indicate challenges in converting revenue into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.85M	6.85M	9.86M	18.51M	1.75M	8.49M
Gross Profit	4.40M	4.20M	6.61M	13.83M	-2.96M	2.89M
EBITDA	-19.96M	-18.37M	-18.71M	-16.19M	-24.83M	-17.55M
Net Income	-20.83M	-19.38M	-20.35M	-19.70M	-26.63M	-18.37M
Balance Sheet
Total Assets	52.81M	60.72M	70.35M	100.58M	21.73M	19.61M
Cash, Cash Equivalents and Short-Term Investments	20.68M	29.42M	43.44M	81.33M	6.14M	4.98M
Total Debt	151.89K	21.97M	5.83M	15.98M	10.63M	202.68K
Total Liabilities	27.74M	29.85M	21.01M	33.94M	15.03M	6.73M
Stockholders Equity	25.06M	30.87M	49.34M	66.64M	6.70M	12.88M
Cash Flow
Free Cash Flow	-27.94M	-30.04M	-34.63M	-9.48M	-28.00M	-19.33M
Operating Cash Flow	-27.42M	-29.59M	-33.67M	-8.86M	-26.61M	-17.89M
Investing Cash Flow	-527.89K	-449.13K	5.85M	-597.57K	-1.40M	-1.29M
Financing Cash Flow	16.08M	16.08M	-10.05M	84.00M	29.17M	14.29M

Heidelberg Pharma AG Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.62
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HPHA, the sentiment is Positive. The current price of 4.62 is above the 20-day moving average (MA) of 4.36, above the 50-day MA of 3.78, and above the 200-day MA of 2.82, indicating a bullish trend. The MACD of 0.23 indicates Negative momentum. The RSI at 62.79 is Neutral, neither overbought nor oversold. The STOCH value of 69.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:HPHA.

Heidelberg Pharma AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HPHA	56 Neutral	€215.30M	―	-59.35%	―	-24.29%	-13.92%
Sector *	52 Neutral	$7.49B	0.22	-61.87%	2.28%	16.62%	1.08%
0R6U		€5.02M	―	-288.87%	―	―	―
0N6Z		€1.39B	61.76	-4.72%	0.10%	―	―
0RFI		€40.85M	―	-111.86%	―	―	―
MEDOF		$388.62M	23.84	2.99%	―	―	―
FYB	57 Neutral	€509.62M	5.89	-26.06%	―	-10.32%	-250.76%